This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ensign Group (ENSG) Buys Facilities in Arizona & Colorado
by Zacks Equity Research
Ensign Group (ENSG) expands its footprint by acquiring skilled nursing facilities in Arizona and Colorado, enhancing its healthcare services and real estate portfolio.
Organon (OGN) Just Overtook the 20-Day Moving Average
by Zacks Equity Research
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?
Tenet Healthcare (THC) Gains 89% in a Year: More Room to Run?
by Zacks Equity Research
Tenet Healthcare (THC) is well-poised to gain from improved volumes, expansion of specialty services, streamlining operations and operational efficiency.
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
by Zacks Equity Research
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Centene (CNC) Expands CHS Network, Shifts AcariaHealth Facility
by Zacks Equity Research
Centene's (CNC) subsidiaries, CHS and AcariaHealth, enhance patient outcomes with CHS' CIPA entering Virginia and AcariaHealth's pharmacy facility relocating to Chesterfield, thereby expanding CNC's capabilities.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Is WisdomTree U.S. SmallCap Dividend ETF (DES) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DES
Zacks.com featured highlights include Vital, Sprouts Farmers, Royal Caribbean, Agnico and Organon
by Zacks Equity Research
Vital, Sprouts Farmers, Royal Caribbean, Agnico and Organon have been highlighted in this Screen of The Week article.
5 Relative Price Strength Stocks With Strong Return Potential
by Nilanjan Choudhury
VITL, SFM, RCL, AEM and OGN are five stocks with explosive relative price strength.
Why You Should Add Encompass Health (EHC) to Your Portfolio Now
by Zacks Equity Research
Encompass Health (EHC) remains well-poised for growth on the back of robust demand for effective inpatient rehabilitation services, joint ventures and solid cash reserves.
Nexstar Media and ASGN have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Nexstar Media and ASGN have been highlighted as Zacks Bull and Bear of the Day.
Is Stagflation Round the Corner? 3 Ultra-Safe Picks
by Tirthankar Chakraborty
Since it's becoming difficult to downplay the idea of stagflation, investors should place their bets on ultra-safe stocks such as Western Union (WU), Frontline (FRO) and Organon (OGN).
Surging Earnings Estimates Signal Upside for Organon (OGN) Stock
by Zacks Equity Research
Organon (OGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Best Value Stocks to Buy for May 13th
by Zacks Equity Research
OGN, ODP and ASC made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 13, 2024.
What Makes Organon (OGN) a New Buy Stock
by Zacks Equity Research
Organon (OGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Organon (OGN) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Organon (OGN) delivered earnings and revenue surprises of 25.77% and 3.44%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Organon (OGN) Gears Up to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Organon's (OGN) first-quarter results are likely to reflect growth in its biosimilars and established brand franchises with lighter fertility product sales amid foreign exchange headwinds.
Earnings Preview: Surgery Partners (SGRY) Q1 Earnings Expected to Decline
by Zacks Equity Research
Surgery Partners (SGRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stay Ahead of the Game With Organon (OGN) Q1 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Organon (OGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.
Earnings Preview: Organon (OGN) Q1 Earnings Expected to Decline
by Zacks Equity Research
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Organon (OGN) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
Organon (OGN) reachead $18.71 at the closing of the latest trading day, reflecting a +1.03% change compared to its last close.
Organon (OGN) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Organon (OGN) stood at $18, denoting a +1.01% change from the preceding trading day.
Should WisdomTree U.S. SmallCap Dividend ETF (DES) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DES
Organon (OGN) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
In the latest trading session, Organon (OGN) closed at $17.71, marking a +1.49% move from the previous day.
Molina (MOH) Wins Deal to Serve Michigan's Medicaid Members
by Zacks Equity Research
Molina Healthcare (MOH) wins a Medicaid contract from the MDHHS to better care for the healthcare needs of Michigan's Medicaid beneficiaries and therefore, gain more customers.